Annual Biopharma Fee Estimates Need More Transparency, BIO Says
Executive Summary
The biopharmaceutical industry is pushing for greater transparency around the data used by the federal government to generate preliminary estimates of the market-based fees owed to the government by individual manufacturers and importers in 2011.
You may also be interested in...
IRS Annual Fee Rule For Brand Drug Manufacturers Clarifies Orphan Drug Exclusion, Part B Calculations
Policies outlined in the temporary rule will remain "applicable" until at least Aug. 15, 2014.
IRS Annual Fee Rule For Brand Drug Manufacturers Clarifies Orphan Drug Exclusion, Part B Calculations
Policies outlined in the temporary rule will remain "applicable" until at least Aug. 15, 2014.
Market-Based Drug Fees: IRS Will Release 2011 Estimates In May, Guidance Says
The IRS guidance proposes a method for calculating the fees and sets out a timetable for the process in 2011, the program's first year. The guidance also describes what corporate entities are liable for the fees and what branded drugs are covered.